Dupont Capital Management Corp Decreases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Posted by Defense World Staff on Jul 22nd, 2023

Dupont Capital Management Corp reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 77.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,453 shares of the biopharmaceutical company’s stock after selling 8,191 shares during the quarter. Dupont Capital Management Corp’s holdings in Halozyme Therapeutics were worth $94,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Artisan Partners Limited Partnership raised its holdings in shares of Halozyme Therapeutics by 16.5% during the fourth quarter. Artisan Partners Limited Partnership now owns 7,140,953 shares of the biopharmaceutical company’s stock valued at $406,320,000 after acquiring an additional 1,013,061 shares in the last quarter. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $53,957,000. Two Sigma Investments LP increased its position in shares of Halozyme Therapeutics by 414.4% during the fourth quarter. Two Sigma Investments LP now owns 551,074 shares of the biopharmaceutical company’s stock valued at $31,356,000 after buying an additional 443,935 shares during the period. UBS Asset Management Americas Inc. increased its position in shares of Halozyme Therapeutics by 194.0% during the third quarter. UBS Asset Management Americas Inc. now owns 519,951 shares of the biopharmaceutical company’s stock valued at $20,559,000 after buying an additional 343,087 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Halozyme Therapeutics by 185.5% in the first quarter. Assenagon Asset Management S.A. now owns 452,984 shares of the biopharmaceutical company’s stock worth $17,299,000 after buying an additional 294,313 shares in the last quarter. Hedge funds and other institutional investors own 92.93% of the company’s stock.

Halozyme Therapeutics Trading Up 0.8 %

Shares of NASDAQ HALO opened at $42.89 on Friday. The firm’s 50 day moving average price is $35.44 and its 200-day moving average price is $40.36. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $59.46. The company has a debt-to-equity ratio of 22.69, a quick ratio of 5.52 and a current ratio of 6.69. The company has a market cap of $5.65 billion, a PE ratio of 32.74, a P/E/G ratio of 0.64 and a beta of 1.22.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by ($0.01). Halozyme Therapeutics had a net margin of 25.76% and a return on equity of 184.32%. The business had revenue of $162.14 million during the quarter, compared to the consensus estimate of $174.20 million. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $40.43, for a total transaction of $404,300.00. Following the transaction, the senior vice president now owns 141,911 shares in the company, valued at approximately $5,737,461.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research analyst reports. StockNews.com initiated coverage on Halozyme Therapeutics in a report on Thursday, May 18th. They set a “hold” rating on the stock. Berenberg Bank started coverage on Halozyme Therapeutics in a research report on Monday, March 27th. They set a “buy” rating and a $58.00 price objective for the company. Piper Sandler raised shares of Halozyme Therapeutics from a “neutral” rating to an “overweight” rating and set a $46.00 target price on the stock in a research report on Wednesday, May 10th. Finally, TheStreet cut shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Tuesday, June 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.78.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.